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Objectives. The present study was designed to identify the
hemodynamic factor or factors that reflexly contribute to activa-
tion of the cardiac sympathetic nerves in patients with severe
congestive heart failure (CHF).
Background. We and others have previously shown that activa-
tion of the sympathetic nervous system is a key feature of CHF in
humans. Furthermore, the degree of sympathetic activation shows
marked regional heterogeneity and is most pronounced in the
heart. Recent studies have shown a significant positive relation
between pulmonary artery pressure and the magnitude of cardiac
sympathetic activation. Of particular importance, the degree of
cardiac sympathoexcitation has also been shown to be strongly
associated with mortality in CHF.
Methods. We assessed total systemic and cardiac sympathetic
activity (norepinephrine [NE] spillover method) in nine patients
with severe CHF and significantly elevated pulmonary artery
pressure (mean [6SEM] pulmonary artery pressure 46 6
3 mm Hg) at rest and during a titrated infusion of sodium
nitroprusside (SNP).
Results. SNP infusion significantly reduced mean arterial blood
pressure, pulmonary artery pressure and pulmonary capillary
wedge pressure. During SNP infusion, the total body NE spillover
rate (NESR) increased (from 7.9 6 1.7 to 11.2 6 3.1 nmol/min,
p < 0.01), whereas the cardiac NESR decreased (from 522 6 86 to
409 6 71 pmol/min, p < 0.05). The ratio of cardiac/total NE
spillover was also substantially reduced (from 7.8 6 1.3 to 4.9 6
0.9%, p < 0.001).
Conclusions. There is a directionally opposite change in whole-
body (increase) and cardiac (reduction) sympathetic nervous
activity during SNP infusion, most likely due to unloading of
arterial baroreceptors and specific cardiopulmonary barorecep-
tors, respectively, in severe CHF. These observations support the
concept of a positive feedback relation between pulmonary artery
pressure/filling pressure and cardiac sympathetic tone in CHF
and serve to reinforce the importance of vasodilator therapy in
this condition.
(J Am Coll Cardiol 1998;31:583–7)
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Neurohormonal activation is a well characterized and impor-
tant pathophysiologic component of congestive heart failure
(CHF). Moreover, many of the systems that are reflexly
activated in the setting of reduced cardiac performance are
currently receiving intense attention as targets for pharmaco-
logic intervention (1–3). Sympathetic nervous activation has
been demonstrated both in CHF in patients and in experimen-
tal models of heart failure by multiple means, including
biochemical and neurophysiologic approaches (4–6). The po-
tentially adverse prognostic implications of sympathetic over-
activity in CHF are also becoming increasingly apparent (7,8).
Despite the extensive documentation of sympathetic over-
activity in CHF, the reflex mechanisms responsible for this
process remain unclear. Moreover, the spatial heterogeneity of
sympathetic outflow in CHF (4) invalidates any assumptions
about generalized reflex control of sympathetic tone in this
condition. Activation of cardiac sympathetic nerves occurs
early in the course of CHF (9), and our group has demon-
strated (5) a positive correlation between pulmonary artery
pressures and the extent of cardiac sympathetic activation, as
reflected by the cardiac norepinephrine spillover rate (NESR).
We have also observed (10) a positive correlation between
monoamine turnover in the brain and the cardiac NESR in
CHF that is thought to reflect the central nervous system
mechanism linking afferent neural traffic from the cardiopul-
monary receptors to selective control of sympathetic outflow.
Taken together, these data suggest a direct reflex link between
pulmonary pressure and sympathetic efferent outflow to the
heart.
The aim of the present study, therefore, was to further
investigate the reflex control of cardiac sympathetic activity in
CHF in patients. Total systemic and cardiac sympathetic
activity were investigated by radiotracer methodology. To
specifically investigate the relation between pulmonary artery
pressure and cardiac NESR, we selected a group of patients
with severe pulmonary hypertension and examined the effect
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of lowering pulmonary artery pressure with a titrated infusion
of sodium nitroprusside (SNP) on sympathetic tone.
Methods
Study patients. Nine patients with CHF and significant
pulmonary hypertension form the basis of this study. All
patients had New York Heart Association functional class III
to IV symptoms and had been referred to the Alfred Hospital
Heart Failure Center for consideration for heart transplanta-
tion. Mean (6SEM) left ventricular ejection fraction for the
group was 16 6 3% (Table 1). All patients were treated with
angiotensin converting-enzyme inhibitors, digoxin and diuretic
drugs (Table 1), and these medications were continued
throughout the study period to avoid hemodynamic decom-
pensation secondary to withdrawal of antifailure therapy. All
patients gave written informed consent, and the study was
performed with the approval of the Alfred Hospital Ethics
Review Committee.
Inclusion criteria and catheterization protocol. All cathe-
terization studies were performed in the morning, and patients
were asked not to consume caffeinated beverages on the study
day to avoid additional sympathoexcitation. A thermodilution
catheter (7F, Arrow International) was inserted percutane-
ously under local anesthesia through a right internal jugular
venous introducer sheath for the determination of pulmonary
artery pressures, pulmonary capillary wedge pressure, right
atrial pressure and cardiac output. Cardiac output was deter-
mined from the average of three cardiac output measurements
that varied by ,10%. Arterial blood pressure was determined
invasively through a radial artery cannula. The criteria for
inclusion in the present study were a pulmonary artery systolic
pressure .50 mm Hg or a transpulmonary gradient (mean
pulmonary artery pressure minus mean wedge pressure)
.12 mm Hg, or both, with an arterial systolic blood pressure of
at least 90 mm Hg.
At the completion of the hemodynamic assessment, a
coronary sinus thermodilution catheter (Webster Laborato-
ries) was positioned in the coronary sinus under fluoroscopic
control. The tip of the thermodilution catheter was carefully
noted and confirmed to lie at least 2 cm proximal to the
coronary sinus orifice in all cases by injection of radiographic
contrast medium. In three subjects two right internal jugular
venous sheaths were inserted to allow simultaneous pulmonary
artery pressure recording and coronary sinus catheterization.
Coronary sinus blood flow was subsequently determined as
previously described (11), and simultaneous arterial and cor-
onary sinus blood sampling was performed. Coronary sinus
plasma flow was calculated after determination of each pa-
tient’s hematocrit.
Radiotracer assessment of sympathetic function. A neuro-
chemical approach to measuring total systemic and cardiac
sympathetic activity and neuronal biochemical integrity was
used, as previously described by our group (5). In brief,
radiolabeled L-[7-3H]norepinephrine was continuously infused
(0.5 to 1 mCi/min) through a peripheral vein to achieve a
steady state plasma concentration. The rate of appearance rate
of norepinephrine (NE) in plasma was measured as an indirect
index of “global” sympathetic nervous activity and calculated
as the ratio of the infusion rate for tritiated NE to the plasma
specific activity of NE in plasma, as previously described
(12,13). The cardiac NESR was calculated from the relation
Cardiac NESR 5 @~NECS 2 NEart! 3 NEex 3 NEart!] 3 CSPF,
where NECS and NEart are the plasma NE concentrations in
the coronary sinus and arterial blood; NEex is the fractional
extraction of tritiated NE across the heart; and CSPF is
coronary sinus plasma flow.
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
CHF 5 congestive heart failure
NE 5 norepinephrine
NESR 5 norepinephrine spillover rate
SNP 5 sodium nitroprusside
Table 1. Study Group Characteristics
Pt No./
Gender
Age
(yr) Diagnosis
LVEF
(%)
PAP
(mm Hg)* Medications
1/M 45 IHD 13 109/48 (66) ACEI, dig, furo, prazosin
2/M 54 IHD 35 55/10 (38) ACEI, dig, furo
3/M 62 IHD 11 81/28 (47) ACEI, furo, Ca
4/M 65 IHD 18 74/20 (44) ACEI, furo, Ca, nitrate
5/M 45 IHD 9 98/37 (54) ACEI, dig, furo
6/M 64 IDCM 12 59/30 (42) ACEI, dig, furo
7/M 45 EtOH 12 56/19 (34) ACEI, dig, furo, metoprolol, Ca
8/F 61 IHD 18 84/44 (55) ACEI, dig, furo, hydrochlorthiazide
9/M 56 IHD 19 63/23 (37) ACEI, dig, furo, Ca, nitrate
*Systolic/diastolic (mean). ACEI 5 antiotensin-converting enzyme inhibitor; Ca 5 calcium antagonist; dig 5 digoxin;
EtOH 5 alcoholic cardiomyopathy; F 5 female; furo 5 furosemide; IDCM 5 idiopathic dilated cardiomyopathy; IHD 5
ischemic heart disease; LVEF 5 left ventricular ejection fraction; M 5 male; PAP 5 pulmonary artery pressure; Pt 5
patient.
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SNP infusion. After the completion of baseline hemody-
namic measurements, coronary sinus blood flow determination
and blood sampling, an intravenous infusion of SNP was
commenced. SNP was administered through a peripheral vein
at an initial rate of 0.5 mg/kg body weight per min. The infusion
rate was increased at 5-min intervals, titrated to achieve a
stable reduction in arterial systolic blood pressure of
20 mm Hg or a minimal systolic blood pressure of 90 mm Hg.
At the maximal SNP infusion rate, hemodynamic measure-
ments, coronary sinus blood flow determination and blood
sampling were again performed after 5 min of stable arterial
blood pressure. In subjects where simultaneous hemodynamic
and coronary sinus catheterization was not performed, great
care was taken to ensure that the position of the coronary sinus
catheter was identical to that of the baseline study and that the
arterial blood pressure remained stable during repositioning of
the coronary sinus catheter.
Biochemical assays. On collection, blood samples were
immediately transferred to ice-chilled tubes containing EGTA
and reduced glutathione. Samples were stored on ice and
subsequently separated by centrifugation at 4°C. Plasma sam-
ples were stored at 270°C until assay. The plasma norepineph-
rine concentrations were determined by high performance
liquid chromatography with electrochemical detection (14).
The plasma specific activity of tritiated NE and dihydroxyphe-
nylglycol was determined by performing timed collections of
the detector cell eluant. Radioactivity was measured by liquid
scintillation spectroscopy.
Statistical methods. Results are presented as the mean
value 6 SEM. Where normally distributed, between-group
comparisons were performed by an unpaired Student t test.
Data that were not normally distributed were compared using
the Wilcoxon rank-sum test. The null hypothesis was rejected
at p , 0.05.
Results
Baseline hemodynamic variables and response to SNP.
The baseline hemodynamic characteristics of the study patients
were consistent with their moderate to severe clinical profile
and degree of left ventricular dysfunction. Baseline hemody-
namic variables and the hemodynamic profile during the
maximal dose of the SNP infusion are detailed in Table 2. By
design, the patients included in this report were characterized
by moderate to severely impaired left ventricular function, with
attendant markedly elevated pulmonary artery and pulmonary
capillary wedge pressures. During SNP infusion, there were
significant reductions in systemic arterial, pulmonary artery
and mean pulmonary capillary wedge pressures. In conjunc-
tion, there was a significant increase in cardiac output. In
response to the SNP infusion there was a modest reduction in
coronary sinus blood flow (baseline vs. SNP: 240 6 42 vs.
206 6 31 ml/min, p 5 0.07).
Sympathetic responses to SNP. The arterial plasma NE
concentration was unchanged during SNP infusion (Fig. 1).
This observation was explained by the counterbalancing effects
of a substantial increase in the total systemic NESR (7.9 6 1.7
vs. 11.2 6 3.1 nmol/min, p , 0.01) and an increase in the total
systemic clearance rate for NE from plasma (1.9 6 0.3 vs. 2.6 6
0.5 liters/min, p , 0.05).
In contrast, the administration of SNP significantly reduced
the NESR to plasma across the heart (baseline vs. SNP: 522 6
86 vs. 409 6 71 pmol/min, p , 0.05), as shown in Figure 2. The
extraction of tracer NE across the heart was not altered by the
SNP infusion (baseline vs. SNP: 0.47 6 0.05 vs. 0.48 6 0.05%,
p 5 NS). At rest, cardiac NESR accounted for 7.8 6 1.3% of
the total systemic NESR, and this fell to 4.9 6 0.9% (p ,
0.001) during SNP infusion (Fig. 2).
Table 2. Baseline Hemodynamic Variables and Responses
to Nitroprusside
Baseline
(mean 6 SEM)
Nitroprusside
(mean 6 SEM) p Value
Heart rate (beats/min) 98 6 4 93 6 4 , 0.05
ArterialSYS (mm Hg) 131 6 6 112 6 8 , 0.001
ArterialMEAN (mm Hg) 91 6 4 77 6 5 , 0.001
RA (mm Hg) 11 6 1 8 6 1 , 0.001
PASYS (mm Hg) 75 6 6 55 6 6 , 0.001
PAMEAN (mm Hg) 46 6 3 31 6 4 , 0.001
PCWP (mm Hg) 30 6 2 18 6 2 , 0.001
CO (liters/min) 4.0 6 0.4 4.6 6 0.4 , 0.05
ArterialMEAN 5 mean arterial pressure; ArterialSYS 5 arterial systolic
pressure; CO 5 cardiac output; PAMEAN 5 mean pulmonary artery pressure;
PASYS 5 pulmonary artery systolic pressure; PCWP 5 pulmonary capillary
wedge pressure; RA 5 right atrial pressure.
Figure 1. Effect of SNP infusion on arterial plasma NE concentration,
total NESR and total NE clearance rate. *p , 0.05, **p , 0.01,
baseline versus SNP.
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Discussion
Activation of cardiac sympathetic nerves has been well
documented in human cardiac failure and has recently been
shown (9) to be an early feature of even mild to moderate CHF
failure. Although generalized sympathetic activation is a hall-
mark of CHF, the degree to which cardiac sympathetic activity
increases appears to be considerably greater than that mea-
sured at other sites (4,9). In a previous study (5), we observed
a statistically significant, positive correlation between mean
pulmonary artery pressure and the cardiac norepinephrine
spillover rate. A similar relation between pulmonary artery/left
ventricular filling pressures and muscle sympathetic nerve
activity has also been reported (6,15). Accordingly, in the
present study we aimed to further explore the relation between
pulmonary artery pressures and cardiac sympathetic activity.
The major new finding of the present study is the demonstra-
tion that acute systemic and pulmonary vasodilation induced
by SNP results in directionally opposite changes in cardiac and
systemic sympathetic activity in patients with severe CHF and
pulmonary hypertension. As expected, in our study a fall in
arterial blood pressure was associated with a 42% increase in
the total systemic NSR. In conjunction, there was a substantial
fall in pulmonary artery pressure and a 22% fall in the cardiac
NESR.
To date, the processes involved in the reflex control of
cardiac sympathetic nerves remain incompletely understood.
In the context of cardiac sympathetic regulation specifically,
most studies, both in healthy subjects and patients with CHF,
have concentrated on the relation between alterations in
baroreceptor loading or unloading and heart rate (16–18).
Although these studies consistently demonstrate a reduction in
the gain of the blood pressure–heart rate relation, one poten-
tial confounding factor is the reduced chronotropic response of
the heart to directly infused catecholamines (19), thereby
limiting the usefulness of heart rate changes as a direct
reflection of alterations in cardiac sympathetic nerve activity.
The difficulty in studying cardiac sympathetic function indi-
rectly in CHF in patients by means of heart rate spectral
analysis has also been recently highlighted (20).
In a recent study, Newton and Parker (21) examined the
effect of SNP-induced vasodilation on whole-body and cardiac
NESR in healthy subjects and patients with CHF. As in our
study, acute vasodilation was associated with a substantial
increase in total systemic NESR, although there was little
change in the peripheral plasma NE concentration because of
a coincident cardiac output-dependent rise in the clearance
rate of NE from plasma. Unlike the present study, Newton and
Parker (21) demonstrated that acute vasodilation was associ-
ated with a small, nonsignificant increase in the cardiac NESR
in patients with CHF, that was significantly less than that
observed in subjects with normal left ventricular function. This
observation led Newton and Parker to conclude that this was a
reflection of impaired baroreceptor function. Our study group
differs in two important ways from that of Newton and Parker
(21). By selection, our patients had 1) significantly higher
pulmonary artery and wedge pressures, and 2) in association, a
higher cardiac NESR. Consistent with the reduction in cardiac
NESR seen in the present study, we also observed a significant
reduction in heart rate during SNP infusion. Again, this was
directionally opposite to that observed by Newton and Parker
(21).
Our study therefore suggests that the more marked degrees
of cardiac sympathetic activation observed in severe CHF may
be a direct, reflex consequence of substantially elevated filling
pressures. Under normal circumstances, cardiac sympathetic
tone measured in humans by isotope dilution is increased in
the setting of arterial baroreceptor unloading (21). The effects
of selective cardiopulmonary baroreceptor unloading on car-
diac sympathetic function have not been examined directly to
date. Furthermore, studies addressing the influence of nonhy-
potensive lower body negative pressure on heart rate have
yielded conflicting results (22,23). Consistent with the findings
of our study, previous experimental studies have also suggested
that distention of certain cardiopulmonary baroreceptor
groups may actually increase cardiac sympathetic tone. A
number of studies (24–26) have demonstrated that distention
of the left atrium or pulmonary veins increases heart rate
through a vagal afferent, sympathetic efferent pathway. More
recently, Kurz et al. (27) also showed that left atrial and
pulmonary distention was also associated with a sympatheti-
cally mediated increase in left ventricular contractility.
Clinical implications. In a previous report from our group
(8), we examined the clinical implications of elevated cardiac
sympathetic activity in patients with severe CHF. Using a
multivariate Cox proportional hazards model, we showed that
the cardiac NESR was the most powerful marker of outcome.
Given the apparent reflex influence of pulmonary artery
pressures on cardiac sympathetic activity, it could therefore be
hypothesized that a therapeutic intervention that reduced
filling pressures would potentially impart a beneficial effect on
survival, in part mediated by a reduction in sympathetic drive
to the heart. In this context, Stevenson et al. (28) showed that
Figure 2. Effect of SNP infusion on cardiac NESR and cardiac/total
systemic NESR ratio. *p , 0.05, ***p , 0.001, baseline versus SNP.
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patients with severely impaired left ventricular function and
persistently elevated filling pressures had a substantially poorer
prognosis than patients whose pulmonary capillary wedge
pressure could be lowered to ,16 mm Hg by tailored antifail-
ure therapy. However, not all vasodilators have been shown to
improve outcome in patients with CHF.
The well known beneficial effect of angiotensin-converting
enzyme (ACE) inhibition in heart failure (1,2) may also be
partly mediated by a reflex reduction in cardiac sympathetic
drive. This hypothesis is supported by a follow-up study from
the Cooperative North Scandinavian Enalapril Survival Study
(CONSENSUS) trial (29), in which it was observed that the
beneficial effects of enalapril were seen only in patients with
neurohormonal activation. In a study of the effect of ACE
inhibition on cardiac sympathetic function, Gilbert et al. (30)
showed that lisinopril significantly reduced the concentration
of NE in the coronary sinus, in association with a reduction in
pulmonary artery pressure (30). Moreover, when patients were
stratified according to their baseline coronary sinus NE con-
centration, the apparent antiadrenergic effect of lisinopril was
only evident in patients with a high coronary sinus NE concen-
tration. This patient group was also characterized by having a
trend toward higher pulmonary artery and wedge pressures.
Conclusions. Cardiac sympathoexcitation is a hallmark of
CHF and has been implicated as a key adverse pathophysio-
logic factor. We previously observed a significant positive
correlation between pulmonary artery pressure and cardiac
NESR. In the current study we showed that acute vasodilation
resulted in a reduced cardiac NESR in patients with poor left
ventricular function and high pulmonary pressures. This study
therefore further supports the notion that the distention of
certain intracardiac baroreceptors results in increased sympa-
thetic drive to the failing human heart.
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